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Bleeding complicationsTreatment of coronary artery disease is usually initiated with
antithrombotic agents, since fatal coronary events are always
associated with atherothrombosis. In addition, by the introduction
of 1st generation drug-eluting stents (DESs), the importance of
long-term antiplatelet therapy has increased because of certain
risk of very late stent thrombosis (VLST). Recently, the risk of VLST
has been dramatically decreased with the use of 2nd generation
DES [1]. Therefore, the need for long-term antiplatelet therapymay
have changed. However, prevention of bleeding complications
related to antithrombotic agents is more important than preven-
tion of VLST. These changes of antithrombotic strategy have raised
numerous discussions around the world. The perioperative period
in non-cardiac surgerymay be one of the highest risk conditions for
bleeding. Yamamoto et al. [2] focused on the bleeding complica-
tions after percutaneous coronary intervention (PCI) using DES
comparing single antiplatelet therapy (SAPT) to double antiplatelet
therapy (DAPT) in the perioperative period. Therewas no beneﬁt in
the DAPT group and there were more bleeding complications as
compared with the SAPT group. This is an important message for
interventional cardiologists who tend to keep DAPT driven by the
fears of stent thrombosis.
The standard antiplatelet therapy for ischemic heart disease,
especially after PCI, is aspirin. P2Y12 receptor antagonists such as
clopidogrel, prasugrel, and ticagrelor have also become standard
medications for acute coronary syndrome (ACS) and PCI with
stenting. Since these medications have potent antiplatelet effects
when used together, the risk of bleeding remains a signiﬁcant
issue [3]. The Antithrombotic Trialists’ Collaboration demonstrat-
ed a meta-analysis of 287 studies with 135,000 patients in a
comparison of antiplatelet therapy versus control [4]. The overall
rate ofmajor bleedingwas 1.13% in the antiplatelet therapy group
with an increase in risk of 1.6. The antithrombotic effect of
aspirin is dose-independent in the range from 30 to 1300 mg by
inhibiting thromboxane A2, whereas gastroenteric toxicity is
dose-dependent due to the inhibition of cyclooxygenase (COX)
and due to the direct chemical toxicity. Althoughmonotherapy ofDOI of original article: http://dx.doi.org/10.1016/j.jjcc.2014.02.027
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incidence of major bleeding [5], major bleeding such as intracranial
hemorrhage is relatively high in combination therapy with aspirin.
Therefore, low-dose aspirin is usually responsible for both gastro-
enteric and intracranial bleeding. It may be reasonable that
consideration for stopping aspirin instead of P2Y12 receptor
antagonists after DAPT duration is in fashion around the world.
With regard to the perioperative period, it may be difﬁcult to
maintain P2Y12 receptor antagonists as SAPT, because they are
more potent thanaspirin in termsof antiplatelet effect. Themajority
of bleeding events are not life threatening. However, major
hemorrhage is associated with increased myocardial infarction
and stroke in the perioperative period [6] (Fig. 1). Therefore, it is
important to reduce bleeding complications after PCI for patient
outcomes.
Ithasbeendemonstrated thatnon-cardiac surgery is requiredat a
rate of more than 4% per year after DES implantation in Japan [7].
Therefore, a considerable number of stented patients have to
undergo non-cardiac operations during follow-up in their life.
According to the guidelines for perioperative management, aspirin
should be continued until the day of operation for coronary stents
implantation in high-risk patients, except for surgery in a closed
space (i.e. neurosurgery) [8]. It has been demonstrated that
discontinuation of aspirin was associated with higher risk of
cardiovascular events in a large-scale meta-analysis [9]. However,
many surgeons try to avoid operations under any antiplatelet
therapy, even with aspirin alone, in the real world. Recently, it has
been demonstrated that in patients undergoingnon-cardiac surgery,
giving aspirin before surgery and throughout the early post-
operative period fails to decrease the risk of death or non-fatal
myocardial infarction (MI) and is associated with a signiﬁcantly
increased risk of major bleeding [10]. This study may not be
applicable for patients with DES implantation, considering the fact
that only selected patients received coronary stents. There are still
limited data concerning perioperative stent thrombosis in patients
with DES [11–13]. Heparin and low-molecular weight heparin
cannot be considered as perioperative bridging for antiplatelet
therapy since they do not have any antiplatelet effects nor is there
any clinical evidence for their use. Therefore, the remaining majorreserved.
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Fig. 1. Mechanism of increased mortality in patients with bleeding complications after stent implantation.
Table 1
Hemorrhagic risk in noncardiac surgery.
Surgical hemorrhagic risk Blood transfusion requirement Type of surgery
Low Usually not required Peripheral, plastic and general surgery, biopsies; minor orthopedic, otolaryngology, and
general surgery; endoscopy; eye anterior chamber; dental extraction and surgery
Intermediate Frequently required Visceral surgery; cardiovascular surgery; major orthopedic, otolaryngology, urologic
reconstructive surgery
High Possible bleeding in a closed space Intracranial neurosurgery; spinal canal surgery; eye posterior chamber surgery
Modiﬁed from Korte et al. [15].
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antiplatelet agents after 2nd generation DES, either with or without
heparin bridging.
Non-cardiac surgery after DES implantation may be one of the
most critical conditions for both thrombotic and bleeding
complications as previously described. The risk of perioperative
stent thrombosis has been well established in patients undergoing
non-cardiac surgery early after PCI even with bare metal stents. It
was demonstrated that patients undergoing non-cardiac surgery
had increased mortality within 6 weeks after PCI compared with
patients undergoing surgery after 6 weeks [14]. Surgery inevitably
induces bleeding by its nature. Activation of platelets is initiated by
the bleeding. Antiplatelet agents inhibit platelet aggregationwhich
affects both hemostasis and thrombus formation. The beneﬁt–risk
ratio of antiplatelet therapy depends on the absolute risk of
thrombotic and hemorrhagic events in the individual patients at
the perioperative period. For example, antiplatelet therapy is
beneﬁcial for patients with high risk of thrombotic events such as
acute coronary syndrome and complex lesions, but is harmful for
patients with major surgery, neurosurgery, and active gastrointes-
tinal bleeding. Risk stratiﬁcation for both thrombotic and hemor-
rhagic events and discussion among surgeons, anesthesiologists,
and cardiologists would be important before the operation [15,16]
(Table 1). It is necessary to say that appropriate informed consent
from the patients should be given prior to surgery in such cases.
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